In metastatic NSCLC and melanoma, characterized by higher plasma FGL1 levels, poor outcome is found following anti-PD-1 therapy, indicating that FGL1 may play a role in tumor immune resistance (43). This evidence concerns the gene FGL1 and neoplasm.